Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DPI-386 Nasal Gel for Motion Sickness Prevention
NCT04219982Phase 3Terminated
- Sponsor
- Defender Pharmaceuticals
- Start
- Jun 2018
- Primary completion
- Jan 2019
- Modality
- Placebo
- Countries
- 1
01
Overview
A Phase 3 trial of placebo gel (Naval Aeromedical Research Unit, Dayton) in motion sickness, sponsored by Defender Pharmaceuticals. Started Jun 2018; status: terminated.
02
Drugs
placebo gel (Naval Aeromedical Research Unit, Dayton)
03
Conditions
motion sickness
Beyond the preview
Go deeper on NCT04219982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04219982.